Leumas, a deeptech startup focused on transforming manufacturing in the pharmaceutical and wellness industries, has secured $2.2 million in seed funding. The funding round was led by Capital 2B, with participation from Capital-A and Anicut Capital. The company aims to replace traditional, rigid factory systems with intelligent, software-defined infrastructure.
These modular production lines are designed to adapt in real time to different formulations and volumes. “Pharma and wellness brands today need more than just capacity. They need agility, traceability, and the ability to scale without being restricted by outdated infrastructure,” said Subhajit Biswas and Nitesh K, co-founders of Leumas.
Leumas addresses a growing segment of the outsourced manufacturing market, which is projected to surpass $400 billion globally by 2030. Brands increasingly require on-demand production capabilities for personalized medicine and complex wellness products. Vibhore Sharma, partner at Capital 2B, said, “They are solving a global challenge: manufacturing that is slow, expensive, and hard to scale.
Leumas secures major funding boost
Their integration of advanced robotics and intelligent software, along with a delivery model that is easy for brands to adopt, makes them truly differentiated.
Ankit Kedia, founder of Capital-A, said, “Leumas delivers a rare combination of deep technical expertise and operational clarity. Their approach stands out in industries where speed, compliance, and adaptability are essential.”
Leumas’ platform integrates AI-powered robotics, vision-based quality control systems, and autonomous operations to allow continuous, unmanned, and traceable production.
The company has collaborated with major wellness brands, scaling over 120 products across India, the US, and the MENA region. It has also signed partnerships with pharma and food research institutions to launch pilot factories. “Leumas is showing the world what the future of manufacturing looks like—modular, intelligent, and instantly scalable,” said Ajay Anand, partner at Anicut Capital.
The startup plans to utilize the funds to enhance its research and development efforts and expand its modular manufacturing capabilities. Leumas’ innovative approach in integrating robotics with manufacturing processes aims to streamline production, improve precision, and reduce operational costs within the pharmaceutical industry. Given the increasing demand for automation and efficiency in pharmaceutical production, Leumas is well-positioned to address key challenges faced by the sector with its advanced technology solutions.
The infusion of new capital is expected to accelerate the development and deployment of their robotic solutions significantly.
Deanna Ritchie is a managing editor at DevX. She has a degree in English Literature. She has written 2000+ articles on getting out of debt and mastering your finances. She has edited over 60,000 articles in her life. She has a passion for helping writers inspire others through their words. Deanna has also been an editor at Entrepreneur Magazine and ReadWrite.
